Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Olufemi Ogundeji

Addiction Psychiatry Shreveport, LA Medical Doctor

NPI 1912226697 CMS profile 1382904

1006 Highland Ave, Brentwood Hospital, Shreveport, LA 71101

Open in the dashboard

General payments

$7,582

428 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Olufemi Ogundeji of Shreveport, LA is reported in the CMS Open Payments database as having received $7,582 across 428 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Addiction Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,760 83
2024 General $1,062 57
2023 General $1,692 96
2022 General $684 45
2021 General $1,349 85
2020 General $426 26
2019 General $609 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Olufemi Ogundeji
  • Addiction Psychiatry median
  • Middle half of Addiction Psychiatry
  • National median

In program year 2025, general payments to Olufemi Ogundeji were reported at $1,760. Among 180 Addiction Psychiatry profiles paid that year, the median was $138 and the middle half received between $45 and $421.

Show as a table
Year Olufemi Ogundeji Addiction Psychiatry median Middle half National median
2019 $609 $142 $56–$476 $163
2020 $426 $78 $21–$210 $114
2021 $1,349 $112 $35–$458 $132
2022 $684 $113 $39–$343 $149
2023 $1,692 $134 $47–$429 $160
2024 $1,062 $129 $42–$349 $164
2025 $1,760 $138 $45–$421 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $1,106 59 payments
  2. AbbVie, Inc. $921 71 payments
  3. Teva Pharmaceuticals USA, Inc. $798 43 payments
  4. Lundbeck LLC $739 39 payments
  5. Otsuka America Pharmaceutical, Inc. $700 38 payments
  6. Janssen Pharmaceuticals, Inc $569 29 payments
  7. Neurocrine Biosciences, Inc. $491 26 payments
  8. ITI, Inc. $423 23 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $339 20 payments
  10. Sunovion Pharmaceuticals Inc. $312 24 payments
  11. Other $1,184 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,477 424 payments
  2. Education $105 4 payments
Products named General payments · program years 2019–2025
  1. ARISTADA Cns $853 49 payments
  2. ARISTADA Cns $853 49 payments
  3. ARISTADA Cns $726 42 payments
  4. ARISTADA Cns $726 42 payments
  5. LYBALVI $719 35 payments
  6. VRAYLAR $693 59 payments
  7. REXULTI Psychiatry $567 29 payments
  8. INVEGA SUSTENNA $564 28 payments
  9. REXULTI Psychiatry $488 25 payments
  10. INGREZZA $473 25 payments
  11. Other $5,138 268 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

1,806

Median for Psychiatry: 574

Drug cost

$94,473

Median for Psychiatry: $27,624

Branded share of claims

14.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 16 $21,793
Vraylar Cariprazine Hcl Brand 12 $19,210
Eliquis Apixaban Brand 37 $14,051
Trintellix Vortioxetine Hydrobromide Brand 22 $13,372
Aripiprazole Generic 57 $2,586
Oxcarbazepine Generic 48 $1,807
Quetiapine Fumarate Generic 145 $1,740
Trazodone Hcl Generic 107 $1,378
Clozapine Generic 12 $1,291
Gabapentin Generic 95 $1,248

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$20,070

Medicare's payments for the services billed

Medicare patients

131

Average age 60

Services billed

422

62 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 49%
Diabetes 41%
COPD 34%
Alzheimer's or dementia 29%
Ischemic heart disease 26%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $171
$171 12 —
REXULTI
  • Lundbeck LLC $75
  • Otsuka America Pharmaceutical, Inc. $52
$127 16 —
PERSERIS
  • Indivior Inc. $118
$118 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $108
$108 — —
ARISTADA
  • Alkermes, Inc. $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

428 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Psychiatry in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record